Multiple Sclerosis Clinical Trial
Official title:
Armergometry to Improve Mobility in Chronic Progressive Multiple Sclerosis
Chronic progressive multiple sclerosis patients will be randomised to home-based arm ergometry training for 12 weeks or a waitlist control group which will have access to the treatment after 12 weeks when primary endpoint assessment has been obtained. Assessments include clinical outcomes and questionnaires as well MRI imaging and transcranial magnetic stimulation paradigms. Primary endpoint will be the 6 minute walking test at week 12.
Short protocol Design: Patients with progressive MS (PPMS, SPMS) and moderate disability
(Expanded Disability Status Scale 4-6.5) will be randomized to home-based arm ergometry or a
waitlist control group. Home-based training will be supervised by SD-card documentation,
telephone, email and personal contact.
Inclusion criteria: clinically definite MS according to Poser (1983), no progression in the
last 6 months before starting, no acute relapse, age 18- 65 years, EDSS 4-6.5, able to
perform all arm- and handfunctions in daily life, able to execute a daily Training.
Exclusion criteria: medical contraindications for exercise therapy like cardiovascular or
major orthopedic disease, metal parts in body, substantial cognitive deficit, cardiac
pacemaker or other electric implants, pregnancy, epilepsy.
Recruitment sample: n=50 Participants for analysis: n= 40 Control group: Intervention
available after 3 months Duration: 3 months, data acquisition until 12 months after
intervention Hypothesis: Arm ergometry improves walking ability (measured by 6-Minute Walk
Test, 6MWT). Secondary endpoints include cognition, fatigue, depression, life quality and
blood markers as BDNF.
Primary endpoint: Walking ability is evaluated before and after the training program (12
weeks) using the 6MWT by measuring the total walking distance within six minutes.
Secondary endpoints:
1. Walking abilities: 25FWT, TUG, 5SST, 9HPT, 7-day-accelerometry, MSWS- 12, Walking
analysis on Gaitrite tapestry and with kinect camera with different tasks: normal
speed, maximal speed, turning around and double tasking
2. EDSS (Expanded Disability status scale)
3. Fitness measures: areobic fitness (peak oxygen consumption VO2), bioimpedance analysis,
DIERS-Myoline Muscle Strength Measurement, dynamic hand force measurement,
spiroergometry, accelerometry
4. Neuropsychology: Test battery for Attentional Performance (TAP) including alertness,
incompatibility and crossmodal integration, Verbal Learning- and Memory- Test (VLMT),
Brief International Cognitive Assessment for MS (BICAMS), Symbol- Digit- Modalities
Test (SDMT)
5. Questionnaires: HAQUAMS, Fatigue Scale for Motoric and Cognition (FSMC), Beck-
Depressions- Inventar (BDI), Frenchay Activity Index (FAI)
6. cMRT
7. Blood: Neurofilament light, BDNF, Analysis with ELISA
Intervention:
Intervention will be a home-based, individual training with 5 -7 training sessions each
week. Each individual training is based on the results of the spiroergometry of the
participants. These tests will be conducted at the Competence Center for Sports and Exercise
Medicine. The training sessions should be in the areobic exercise sector. In this sector
intensity should be conducted at a power, which shows lactate values around 1.5 mmol, RER
(Respiratory Exchange Ratio) should be around 0.91 and the subjective stress, measured on
Borg-Scale, should be about 11. The V02max should be not higher than 65 %.
Before starting the training at home, patients have to come to the center for adaptation to
the training machine, the "Motomed". We will test, if the power for the training estimated
from stepwise arm ergometry is adeqaute. The patients will recieve an introduction for
motomed as well as information on how to handle the chipcards. Patients will get 3 chipcards
with one training program on each. The first card contains 10 training sessions. One
training range includes 6 minutes active training followed by 2 minute passive rotation by
the motomed. Every minute the direction of the crank changes. The frequency should not be
higher than 60- 80 U/min. Patients have to repeat one training range (6min load, 2 minute
rest) as often as possible. They will recieve one training plan for orientation. After 4
weeks the patients change the chipcard and they start their training with card number 2.
Card number 2 includes the same training program as card number 1, but the power increases
about 20-30 %. The results of everyday training will be saved automatically on the
chipcards. Stored parameters will be heartrate, the power measured in Watt, the length of
the training, the number of training ranges, and the frequency on the crank. Furthermore,
patients make notes regarding their results and their perceived exertion during the training
(measured by Borg-scaling) on a documentation sheet. If the training is too hard, the
patients can either train for a shorter time, they can stop the training or they can use the
chipcard with the lower power.
Procedure: After basline-examinations (walking ability, fitness, neuropsychology, blood
draw, questionnaires, cMRT without contrast medium), instruction on "Motomed" and training
at center, patients will be provided with the machines at their homes and start their
training for 12 weeks under supervision (Email, telephone, home visit). Follow-up will be
performed with the same assessments as at baseline including stepwise ergometry. For the
assessments 2-3 appointments at the center are necessary.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|